# BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
Canonical URL: https://biopharmsignal.com/news/BYSI/beyondspring-announces-plinabulin-and-adc-combination-poster-presentation-at-aac-c9a32e06
Ticker: BYSI
Company: BeyondSpring, Inc.
Source: BeyondSpring, Inc.
Published: 2026-03-30 11:30 EST
## Summary

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company...

## Article Body
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR") , taking place on April 17 through 22, 2026 in San Diego, California.

Presentation Details:

Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor

Presenter / Authors: Yingjuan June Lu , Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, Lan Huang

Presentation Time: April 21, 2026, 2PM to 5PM PT

Location: Poster Section 8 at San Diego Convention Center

Session Category: Immunology

Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1

Poster Board Number: 16

Poster Number: 5597

About BeyondSpring BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com Media Contact: PR@beyondspringpharma.com
## Recent Company News
- 2026-06-04 11:00 EST — [BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value](https://biopharmsignal.com/news/BYSI/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-7cdf7bc8) — Source: BeyondSpring, Inc.
- 2026-06-02 11:00 EST — [BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026](https://biopharmsignal.com/news/BYSI/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-b6c4b5ec) — Source: BeyondSpring, Inc.
- 2026-05-18 11:00 EST — [BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting-121bfb8e) — Source: BeyondSpring, Inc.
- 2026-05-13 11:00 EST — [BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BYSI/beyondspring-reports-first-quarter-2026-financial-results-and-provides-corporate-7bef7d23) — Source: BeyondSpring, Inc.
- 2026-04-22 11:00 EST — [BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs](https://biopharmsignal.com/news/BYSI/beyondspring-reports-compelling-new-data-plinabulin-advances-both-the-anticancer-ba2782eb) — Source: BeyondSpring, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)